Key result
Anti MMP-2 ribozyme gene transfer decreased luminal occlusion compared to non-treated allografts at day 30 post transplantation in a mouse model of CAV.
Why the study?
Does anti MMP-2 ribozyme gene transfection reduce luminal occlusion in a mouse model of cardiac allograft vasculopathy?
Does anti MMP-2 ribozyme gene transfection reduce luminal occlusion in a mouse model of cardiac allograft vasculopathy?
Anti MMP-2 ribozyme gene transfection significantly attenuates luminal occlusion in a mouse model of cardiac allograft vasculopathy, suggesting MMP-2 as a potential therapeutic target.
Answers are grounded in this paper and cite their sources.
Supports MMP-2 targeting in experimental CAV; leaves open clinical translation in human allograft vasculopathy.
OBJECTIVE: Proliferation and migration of vascular smooth muscle cells (SMCs) causes intimal thickening during cardiac allograft vasculopathy (CAV). This process requires the degradation or remodeling of extracellular matrix (ECM) surrounding the cells. Imbalance between degradation and accumulation of ECM also contributes to the development of CAV. In this study, we investigated the contribution of matrix metalloprotenases (MMPs), enzymes regulating ECM turnover, to the development of CAV. METHODS: Donor hearts from male DBA mice were heterotopically transplanted to male B10.D2 recipient mice, and harvested at days 15 and 30 post transplantation. We examined expression MMP-2, -3, -9 and -13 of graft vessels using immunohistochemistry. To clarify the role of MMP-2 in CAV, anti MMP-2 ribozyme was delivered into donor hearts just before transplantation, mediated by a hemagglutinating virus of Japan-liposome complex to specifically suppress MMP-2 activity. RESULTS: All MMPs were immunopositive in SMCs from the slightly thickened neointima at day 15. In the advanced stage of intimal thickening at day 30, in addition to increased number of SMCs, accumulation of collagenous fibers was observed; expression of MMP-3, -9 and -13 was decreased. In contrast, MMP-2 expression remained distinctly positive throughout the progression of the vascular remodeling. After the gene transfer of MMP-2 ribozyme, luminal occlusion was significantly decreased compared to non-treated allografts [25.0+/-6.5 vs. 55.1+/-7.0% (P<0.05)] at day 30 post transplantation. CONCLUSION: MMP-2 is a principle MMP throughout the progression of the vascular remodeling in CAV. Anti MMP-2 therapy could therefore be one of the candidates for a supplemental therapy for CAV.
No takes yet. Share an insight, caveat, or question.
Kei Tsukioka (2002) studied Cardiac allograft vasculopathy. Anti MMP-2 ribozyme gene transfection vs. Non-treated allografts was evaluated on Luminal occlusion at day 30 post transplantation (p=<0.05). Anti MMP-2 ribozyme gene transfer decreased luminal occlusion compared to non-treated allografts at day 30 post transplantation in a mouse model of CAV.
Synapse has enriched 10 related papers. Consider them for comparative context: